Physician profile

Hanspreet Kaur

Hematology & Oncology · Wenatchee, WA

NPI 1043236797

$292.11

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Hematology & Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$13.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $134.54 2019
E.R. Squibb & Sons, L.L.C. $48.15 2019-2020
Emd Serono, INC. $28.98 2019
Kyowa Kirin, INC. $16.34 2019
Astellas Pharma US INC $14.90 2020
Janssen Biotech, INC. $13.19 2023 Stelara
Pfizer INC. $12.83 2019
Gilead Sciences, INC. $11.92 2021
Genentech USA, INC. $11.26 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hanspreet Kaur

$292.11

in general payments reported 2019-2025

Years
2019-2023
Top company
Amgen INC.

https://glasscript.com/doctor/819770/hanspreet-kaur

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.